QuidelOrtho (QDEL)
(Delayed Data from NSDQ)
$41.05 USD
-0.92 (-2.19%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $41.04 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.05 USD
-0.92 (-2.19%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $41.04 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
Zacks News
Quidel (QDEL) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Quidel (QDEL) closed the most recent trading day at $127.71, moving -1.98% from the previous trading session.
Quidel Corporation (QDEL) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Quidel's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued robust sales of its SARS-related products.
4 Stocks to Watch Out For as MedTech Rides on Buyout Frenzy
by Debanjana Dey
Here are some MedTech stocks - Quidel (QDEL), Thermo Fisher (TMO), Baxter (BAX) and BD (BDX) - that have been quite active in the acquisition front and therefore worth investor attention.
Quidel (QDEL) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Quidel (QDEL) closed the most recent trading day at $126.80, moving +0.51% from the previous trading session.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics and Quidel Corp.
by Zacks Equity Research
Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics,and Quidel Corp. are highlighted in this analyst blog.
3 Diagnostics Stocks in Focus Amid the Omicron Outbreak
by Riya Anand
Stocks like Thermo Fisher (TMO), QIAGEN (QGEN) and Quidel (QDEL) are expected to gain from increasing testing demand.
Quidel's (QDEL) Antigen Tests Successful in Omicron Detection
by Zacks Equity Research
The success of Quidel's (QDEL) antigen tests against Omicron is expected to lead to better access to affordable COVID-19 testing.
Company News for Dec 27, 2021
by Zacks Equity Research
Companies in the News Are: OCDX,QDEL,JD,TCEHY,TSLA,NKLA
Quidel (QDEL) Inks Buyout Deal to Solidify Its Diagnostics Arm
by Zacks Equity Research
Quidel's (QDEL) latest buyout is expected to expand its point-of-care diagnostics portfolio as well as geographic footprint.
3 Beaten-Down Medical Product Stocks to Buy on a Turnaround in 2022
by Debanjana Dey
Here are some medical product stocks from the MedTech sector - Quidel (QDEL), Cerus (CERS) and NextGen Healthcare (NXGN) - which might be witnessing a turnaround in 2022 and be solid investment options.
Philips (PHG) to Buy Vesper Medical, Expand Vascular Portfolio
by Zacks Equity Research
Philips (PHG) is set to acquire Vesper Medical to strengthen its vascular devices portfolio and customer base.
Quidel (QDEL) Q3 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Quidel (QDEL) records a strong Q3 performance despite lower revenues from two of its product categories.
Quidel (QDEL) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of 516.09% and 0.55%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Quidel (QDEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD's (BDX) New Manufacturing Facility to Boost Supply Readiness
by Zacks Equity Research
BD's (BDX) latest manufacturing line is expected to not only boost supply capacity but also provide priority access to needles and syringes to the U.S. government.
Quest Diagnostics (DGX) Base Arm Recovers, Testing Sales Grow
by Zacks Equity Research
Quest Diagnostics (DGX) is hopeful about the fact that COVID-19 testing remains critical as employees are returning to the workplace and students to the classroom.
Quidel Corporation (QDEL) Reports Solid Preliminary Q3 Revenues
by Zacks Equity Research
Quidel's (QDEL) revenue growth in the third quarter is likely to have been boosted by robust sales of its SARS-related products.
New Strong Sell Stocks for October 6th
by Zacks Equity Research
EQX, LMNR, QDEL, CP, and KAR have been added to the Zacks Rank #5 (Strong Sell) List on October 6, 2021.
Sonos, Tencent, Quest Diagnostics, Quidel and LabCorp highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Sonos, Tencent, Quest Diagnostics, Quidel and LabCorp highlighted as Zacks Bull and Bear of the Day
3 Diagnostics Stocks in Focus on Biden's Delta Variant Mandate
by Riya Anand
Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.
Quidel's (QDEL) QuickVue OTC COVID-19 Test Now Widely Available
by Zacks Equity Research
In-store and online availability of Quidel's (QDEL) QuickVue OTC COVID-19 Test is expected to meet the rising COVID-19 testing needs across the United States.
Quidel (QDEL) Q2 Earnings Fall Shy of Estimates, Margins Down
by Zacks Equity Research
Quidel's (QDEL) dismal Q2 performance stems from lower revenues across majority of its product categories.
Quidel (QDEL) Q2 Earnings Miss Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of -37.50% and 1.91%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Quidel (QDEL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have registered solid product sales during Q2 which are likely to have driven its overall top line.
Earnings Preview: Quidel (QDEL) Q2 Earnings Expected to Decline
by Zacks Equity Research
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.